{"id":59312,"date":"2026-07-22T16:15:10","date_gmt":"2026-07-22T16:15:10","guid":{"rendered":"https:\/\/www.europesays.com\/germany\/59312\/"},"modified":"2026-07-22T16:15:10","modified_gmt":"2026-07-22T16:15:10","slug":"merck-summit-phrma-bayer-celldex-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/germany\/59312\/","title":{"rendered":"Merck, Summit, PhRMA, Bayer, Celldex: Readout Newsletter"},"content":{"rendered":"

\t\t\t\t\t\t\t\t\t\t\t\"\"<\/p>\n

\t\t\t\tAdobe<\/p>\n

\t\t\t\t\t\"\"\"\"\t\t\t\t<\/p>\n

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.<\/p>\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n

Good morning. All my social media feeds have been filled with\u00a0Jimothy the raccoon<\/a>, and I hope your feeds\u00a0now will be too.<\/p>\n

The need-to-know this morning<\/p>\n

Celldex Therapeutics said its experimental drug barzolvolimab failed in a Phase 2 study<\/a> in the skin condition prurigo nodularis, sending its shares down in premarket trading. The company is continuing to test the drug in a number of other indications, with\u00a0data expected in September or October from Phase 3 trials in chronic spontaneous urticaria, which causes chronic hives.\u00a0<\/p>\n

Summit Therapeutics released updated survival data<\/a> from its Phase 3 HARMONi trial testing the drug ivonescimab in a form of\u00a0non-small cell lung cancer. The FDA is set to make an approval decision on the drug in the disease by Nov. 14. \u00a0<\/p>\n

Pharma tries to tamp down broad China restrictions<\/p>\n

From STAT\u2019s Daniel Payne: Pharmaceutical leaders are trying to convince policymakers to back off pushes for aggressive restrictions on investments in Chinese firms.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n

\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/p>\n

National Biotech Reporter<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t<\/p>\n

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n

\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/p>\n

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.<\/p>\n","protected":false},"excerpt":{"rendered":"Adobe Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are…\n","protected":false},"author":2,"featured_media":59313,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21161],"tags":[21182,17984,45011,9874,1383],"class_list":["post-59312","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bayer","tag-bayer","tag-biotechnology","tag-drug-development","tag-drug-prices","tag-research"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/59312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=59312"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/59312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/59313"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=59312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=59312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=59312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}